- Home
- CHR vs DRMA Comparison
CHR vs DRMA Comparison
Compare CHR & DRMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHR
- DRMA
- Stock Information
- Founded
- CHR 2016
- DRMA 2014
- Country
- CHR China
- DRMA United States
- Employees
- CHR N/A
- DRMA N/A
- Industry
- CHR EDP Services
- DRMA Biotechnology: Pharmaceutical Preparations
- Sector
- CHR Technology
- DRMA Health Care
- Exchange
- CHR Nasdaq
- DRMA Nasdaq
- Market Cap
- CHR 2.5M
- DRMA 2.9M
- IPO Year
- CHR N/A
- DRMA 2021
- Fundamental
- Price
- CHR $0.12
- DRMA $3.70
- Analyst Decision
- CHR
- DRMA Strong Buy
- Analyst Count
- CHR 0
- DRMA 1
- Target Price
- CHR N/A
- DRMA $10.00
- AVG Volume (30 Days)
- CHR 34.1M
- DRMA 359.9K
- Earning Date
- CHR 07-30-2025
- DRMA 11-07-2025
- Dividend Yield
- CHR N/A
- DRMA N/A
- EPS Growth
- CHR N/A
- DRMA N/A
- EPS
- CHR 1.92
- DRMA N/A
- Revenue
- CHR $147,134,000.00
- DRMA N/A
- Revenue This Year
- CHR N/A
- DRMA N/A
- Revenue Next Year
- CHR N/A
- DRMA N/A
- P/E Ratio
- CHR $0.07
- DRMA N/A
- Revenue Growth
- CHR N/A
- DRMA N/A
- 52 Week Low
- CHR $0.11
- DRMA $3.58
- 52 Week High
- CHR $3.45
- DRMA $23.70
- Technical
- Relative Strength Index (RSI)
- CHR 23.42
- DRMA 35.80
- Support Level
- CHR $0.12
- DRMA $3.93
- Resistance Level
- CHR $0.14
- DRMA $4.24
- Average True Range (ATR)
- CHR 0.01
- DRMA 0.28
- MACD
- CHR 0.03
- DRMA -0.03
- Stochastic Oscillator
- CHR 14.93
- DRMA 13.04
About CHR Cheer Holding Inc.
Cheer Holding Inc is a provider of next generation mobile internet infrastructure and platform services in China. It is engaged in building a digital ecosystem that integrates platforms, applications, technology, and industry into a cohesive system, thereby creating a new, open business environment that leverages AI technology. Its portfolio includes various products and services, such as Polaris Intelligent Cloud, CHEERS Telepathy, CHEERS Open Platform, CHEERS Video, CHEERS e-Mall, CheerReal, CheerCar, CheerChat, CHEERS Fresh Group-Buying E-commerce Platform, Digital Innovation Research Institute, CHEERS Livestreaming, variety show series, IP short video matrix, and more.
About DRMA Dermata Therapeutics Inc.
Dermata Therapeutics Inc is a late-stage medical dermatology company focused on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical skin diseases and aesthetic applications. Its two product candidates, XYNGARI (formerly known as DMT310) and DMT410, incorporate its proprietary, multifaceted, Spongilla technology to topically treat a variety of dermatological conditions. Its Spongilla technology platform will enable to development and formulation of singular and combination products that can target topical delivery of chemical compounds into the dermis for maximum treatment effect for a variety of inflammatory skin diseases. Dermata announced positive Phase 3 data from its STAR-1 clinical trial in March 2025.